Talphera (TLPH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual meeting scheduled for June 22, 2026, with voting open until June 21, 2026 at 11:59 PM ET.
Shareholders can access proxy materials online or request paper/email copies by June 8, 2026.
Voting can be completed online or virtually at the meeting.
Voting matters and shareholder proposals
Election of three directors: Marina Bozilenko, Joseph Todisco, and Mark Wan, with board recommending a vote for all.
Ratification of BPM LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote to approve named executive officer compensation.
Approval of Amended and Restated 2020 Equity Incentive Plan.
Approval of Amended and Restated 2011 Employee Stock Purchase Plan.
Provision for other business to be addressed as may properly come before the meeting.
Board of directors and corporate governance
Board recommends all director nominees and all proposals for shareholder approval.
Latest events from Talphera
- Q2 net loss was $4.3M as nafamostat gains guideline support and CRRT market expands 21%.TLPH
Q2 2026 - All proposals, including director elections and plan amendments, were approved without shareholder questions.TLPH
AGM 2026 - NEPHRO CRRT study enrollment surpassed 50%, Q1 net loss was $2.6M, cash at $21.1M.TLPH
Q1 2026 - Board recommends approval of all proposals, including director elections and plan amendments.TLPH
Proxy filing - Niyad targets a major gap in anticoagulation for dialysis, with pivotal study completion expected in 2026.TLPH
Corporate presentation - Resale registration for $4.1M in shares and warrants; acute care focus; no proceeds to issuer.TLPH
Registration filing - Nephro CRRT study hits 50% enrollment; $20.4M cash at year-end 2025; Niyad seen as promising.TLPH
Q4 2025 & Investor Day - Pivotal phase III trial of Niyad targets 2025 finish, with strong IP and market prospects.TLPH
Maxim Group’s 2024 Healthcare Virtual Summit - Q2 net loss narrowed to $3.8M, cash rose to $14M, and NEPHRO study enrollment accelerated.TLPH
Q2 2024